MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

[1]  M. I. Khan,et al.  Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma , 2018, BMC Cancer.

[2]  J. Spangle,et al.  The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[3]  B. Manavathi,et al.  HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation , 2016, Cellular Oncology.

[4]  B. Moshiree,et al.  Syndrome of Inappropriate Anti-Diuretic Hormone Secretion Secondary to Strongyloides stercoralis Infection in an Allogeneic Stem Cell Transplant Patient: A Case Report and Literature Review. , 2017, Transplantation proceedings.

[5]  Jingxian Shen,et al.  Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. , 2017, Oncology letters.

[6]  A. Lánczky,et al.  miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.

[7]  A. Schmid,et al.  PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo , 2016, Clinical Cancer Research.

[8]  P. Mantyh,et al.  Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent , 2016, Breast cancer.

[9]  D. Dávila,et al.  The use of cannabinoids as anticancer agents , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  M. Haberal,et al.  Predictors of Survival in Hepatocellular Carcinoma Patients. , 2015, Annals of transplantation.

[11]  E. Hirsch,et al.  PI3K/AKT signaling pathway and cancer: an updated review , 2014, Annals of medicine.

[12]  Abdel-Naser Elzouki,et al.  Metastatic Hepatocellular Carcinoma to Parotid Glands , 2014, The American journal of case reports.

[13]  A. Ribas,et al.  Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma , 2014, Molecular Cancer.

[14]  L. Kwong,et al.  Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma , 2013, Clinical Cancer Research.

[15]  R. Capasso,et al.  Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer , 2012, Journal of Molecular Medicine.

[16]  L. Marnett,et al.  Cannabinoids, endocannabinoids, and cancer , 2011, Cancer and Metastasis Reviews.

[17]  D. Rimm,et al.  Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma , 2010, Clinical Cancer Research.

[18]  K. Shilo,et al.  Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non–Small Cell Lung Cancer Growth and Metastasis , 2010, Cancer Prevention Research.

[19]  P. Diaz,et al.  Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain , 2010, Anesthesia and analgesia.

[20]  C. la Vecchia,et al.  Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. , 2009, Cancer letters.

[21]  C. Bass,et al.  Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer , 2009, Molecular Cancer Therapeutics.

[22]  M. Camilleri,et al.  Cannabinoids in intestinal inflammation and cancer. , 2009, Pharmacological research.

[23]  W. Wen,et al.  Overproduction of cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: implication for therapy. , 2009, Cancer letters.

[24]  K. Flaherty,et al.  Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. , 2009, The Journal of investigative dermatology.

[25]  F. Cianchi,et al.  Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor α–Mediated Ceramide De novo Synthesis in Colon Cancer Cells , 2008, Clinical Cancer Research.

[26]  P. Diaz,et al.  Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. , 2008, Journal of medicinal chemistry.

[27]  L. Roberts.  Sorafenib in liver cancer--just the beginning. , 2008, The New England journal of medicine.

[28]  A. Carracedo,et al.  Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. , 2008, Cancer research.

[29]  M. Malumbres,et al.  Cannabinoid receptors as novel targets for the treatment of melanoma , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  D. Sarnataro,et al.  The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation through a Lipid Raft-Mediated Mechanism , 2006, Molecular Pharmacology.

[31]  P. Massi,et al.  Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines , 2004, Journal of Pharmacology and Experimental Therapeutics.

[32]  A. M. Sánchez,et al.  Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. , 2003, Cellular signalling.

[33]  E. Cadenas,et al.  Nitric Oxide and Cell Signaling Pathways in Mitochondrial-Dependent Apoptosis , 2002, Biological chemistry.

[34]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[35]  K. Fuxe,et al.  Neuroglobin as a regulator of mitochondrial-dependent apoptosis: a bioinformatics analysis. , 2014, International journal of molecular medicine.